NTT-DOCOMO
16.1.2024 10:11:27 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2024, the world's largest mobile exhibition, in Barcelona, Spain from February 26 to 29. DOCOMO's booth will showcase exhibits of its technological advancement since last year and presentations focused on the core themes of 6G, open radio access networks (Open RAN) and extended reality (XR), aiming to advance international standardization and foster global business opportunities with the implementation of next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116090399/en/
NTT DOCOMO Booth at MWC Barcelona 2024 (Graphic: Business Wire)
For 6G, there will be interactive demonstrations of FEEL TECH,® an innovative technology that revolutionizes the sharing of sensory information between people DOCOMO's Human Augmentation Platform connected to a 6G network. This pioneering technology aims to facilitate clear transmission of sensory information that is often difficult to communicate verbally, paving the way for a new communication culture and providing added value for an enhanced quality of life.
The booth will also provide a glimpse of the coming world of 6G and advanced wireless technologies that DOCOMO is now developing, such as a non-terrestrial network (NTN) incorporating high-altitude platform stations (HAPS),1 which are expected to facilitate the broad extension of communication services beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
For Open RAN, in addition to presenting the OREX®2-branded services (OREX Packages), DOCOMO will introduce the latest initiatives with diverse global vendors and operators since the launch of the OREX to make Open RAN a reality.
For XR, DOCOMO will showcase the first concept model3 of XR glasses from NTT QONOQ Devices, INC.,4 which is scheduled for release around mid-2024, along with images of utilization.
At MWC Barcelona 2024, DOCOMO looks forward to showcasing its cutting-edge technologies and businesses the company is developing under the brand slogan "changing worlds with you."
For more about DOCOMO's exhibits and the overall exhibition, please refer to the appendix.
1 Unmanned vehicles flying in the stratosphere for days or months at a time, using relays to provide mobile connectivity (ranging up to 200 kilometers) in mountainous and remote areas, including at sea and in the air, on a highly cost-efficient basis.
2 OREX Announces OREX® Open RAN Service Lineup https://www.docomo.ne.jp/english/info/media_center/pr/2023/0927_00.html
3 Specifications of final commercial products may differ from the reference exhibits.
4 NTT QONOQ, INC. and SHARP CORPORATION form a joint venture company, NTT QONOQ Devices, INC.
https://www.devices.nttqonoq.com/pdf/20230327.pdf
Human Augmentation Platform, FEEL TECH and OREX are registered trademarks of NTT DOCOMO, INC. in Japan.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2024
1. Exhibitions |
||
Theme |
Exhibit & Demo |
Details |
6G |
Wireless technologies and NTN |
Non-terrestrial network initiatives for 6G and extended coverage, including technical explanations, dioramas and simulators. |
Human Augmentation Platform |
Platform and FEEL TECH technology for sharing sensory information between people. |
|
Open RAN |
Virtual tour of Shared Open Lab |
360-degree, 3D virtual tour of the OREX verification environment. |
Automated network design and maintenance |
Demonstrations of actual systems for automated network design and maintenance. |
|
XR |
Conceptual model of XR glasses |
Mock-up model and video illustrating how these proposed glasses will be used. |
2. NTT DOCOMO Booth Location
Hall 4 Stand 4E50
3. Presentation
Tentative title: Open RAN: Toward Commercialization and Operations
When: Monday, February 26 from 13:15 to 13:45 (local time)
Where: Broadcast Stage, Hall 4
Speaker: Mr. Sadayuki Abeta, OREX evangelist, NTT DOCOMO
Note: Content and schedule are subject to change. Please see MWC Barcelona 2024 for the latest information.
Reference
MWC Barcelona 2024
https://www.mwcbarcelona.com/
1. Dates & Times
February 26 to 29
08:30 to 19:00, but 08:30 to 16:00 on last day (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116090399/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom